Hyplaxy (Hydroxychloroquine Sulfate)

Hydroxychloroquine accumulates in acidic cellular compartments, raising the pH and disrupting lysosomal function. In malaria parasites it blocks heme polymerization, causing toxic heme buildup. In immune cells it interferes with antigen processing and cytokine release, thereby reducing inflammatory activity.

The dosage of Hyplaxy is individualized by the prescribing clinician based on the specific indication, patient weight, renal and hepatic function, and other clinical factors. Only a qualified healthcare professional should determine the appropriate regimen.

Safety data for hydroxychloroquine in pregnancy and lactation are limited. It should be used only if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by the treating physician in consultation with the patient.

To request Hyplaxy, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with chloroquine, hydroxychloroquine has a broader safety margin and additional immunomodulatory effects, making it useful for autoimmune diseases. Unlike newer agents such as artemisinin‑based combinations, it is taken orally once or twice daily and requires monitoring for retinal and cardiac toxicity.

Hyplaxy tablets should be stored at ambient temperature, preferably below 25 °C, in their original container to protect from moisture and light. Keep the product out of reach of children and avoid storing in areas with high humidity or direct sunlight.

Hyplaxy is supplied as oral tablets that are swallowed whole with a glass of water. It is taken by mouth according to the schedule prescribed by the healthcare provider, typically with or without food as directed.

The most serious adverse effects include retinal toxicity that can lead to irreversible vision loss, cardiac complications such as arrhythmias or cardiomyopathy, and severe hypoglycemia, especially in patients receiving insulin or other glucose‑lowering agents.

Hyplaxy is contraindicated in individuals with known hypersensitivity to hydroxychloroquine or related compounds, pre‑existing retinal disease, severe cardiac conduction disorders, or significant hepatic or renal impairment without appropriate dose adjustment.